2009-11-04 12:20:44 - Terra med Alliance News:The model opens the door to further investigation into a rare and often fatal blood cancer.

Terra med Alliance News: Researchers at the University of Minnesota Cancer Center have produced the first genetically-engineered mouse that provides a model of infant acute lymphoblastic leukemia (ALL). The mouse model opens the door to further investigation into the biology, treatment, and possibly cure of infant acute lymphoblastic leukemia (ALL).
Terra med Alliance News: Laboratory Model Makes Further Research Possible
ALL is an often fatal cancer that usually strikes children from infancy to one year of age. Infant ALL currently affects about 200 babies each year in the United States, and claims as many as 60 percent before their first birthday.
An abnormally formed gene is considered to be the source of the disease. While researchers have long known the gene, the

absence of a laboratory model to more intensely study the disease has frustrated researchers for nearly two decades. With an experimental model, exploring and designing treatments has been possible. "Hopefully, this mouse will help us find a cure so that in the not too distant future, a parent does not have to experience the agony of losing a baby to this cancer," said John Kersey, M.D. & Dr. Kersey led the research team and is a physician and researcher specializing in childhood cancers and director of the University's Cancer Center.
Next, Kersey and his colleagues plan to research drugs that may provide better treatment options for infant ALL.
Terra med Alliance News: Model Provides Hope for Child and Adult Patients
Like all leukemias, infant ALL is an acquired, not inherited, genetic disease. DNA, which contains the code for a person's genetic structure, goes through a normal process of breaking and rejoining. During this replication process, researchers believe the genetic material in a few bone marrow cells gets damaged, resulting in cancer.
"Sometimes a mistake happens in the rejoining of the DNA and the result can be leukemia," Kersey said. "In about 75 percent of infants with infant ALL, the genetic rearrangement occurs in the womb as the baby is developing. We believe the genes fuse by mistake and form the basis for infant ALL."
Adults can also get the disease. About two-thirds of them die on average within two years of diagnosis. Many adults develop this disease as a secondary cancer, having been previously treated with chemotherapy or radiation for another cancer, such as breast cancer.
Kersey collaborated with these colleagues on this research: Weili Chen, Quanzhi Li, Ph.D., Wendy Hudson, Ashish Kumar, M.D., Ph.D., and Nicole Kirchhof, all with the University of Minnesota Cancer Center. The research was funded by a grant from the National Institutes of Health (NIH) and the Children's Cancer Research Fund (CCRF).

Terramed Alliance is a non-profit organization in the battle against leukemia helps children living with cancer and their families. Our goal is to make sure children battling cancer know they are not alone. For more information please visit www.terramedalliance.org. Email at contact@terramedalliance.org